Annals of Oncology Advance Access originally published online on January 17, 2007
Annals of Oncology 2007 18(4):689-693; doi:10.1093/annonc/mdl478
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 European Society for Medical Oncology
breast cancer |
Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients—a double-blind, randomized study
1 Department of Obstetrics and Gynecology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany
2 German Breast Group, Schleussnerstr. 42, 63263 Neu-Isenburg, Germany
* Correspondence to: Dr S. Loibl, J.W. Goethe-University Hospital, Department of Obstetrics and Gynecology, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany. Tel: +49-69-6301-7024; Fax: +49-69-6301-7938; E-mail: loibl{at}em.uni-frankfurt.de
Background: Classical hormone replacement therapy for hot flashes is contraindicated in breast cancer especially in endocrine responsive disease.
Patients and methods: In a double-blind, randomized phase III study, breast cancer patients suffering from hot flashes at least twice a day, who were not taking any medication against hypertension and depression received either clonidine 0.075 mg twice a day or venlafaxine 37.5 mg twice a day for 4 weeks. The primary end point was defined as the frequency of hot flashes after 4 weeks of treatment. A self-reported 1-week hot flash and other symptom questionnaire were kept before the start of treatment until the end of treatment course.
Results: From April 2002 to October 2004, 80 patients were recruited of whom 64 were assessable for efficacy analyses. Thirty-three received clonidine and 31 venlafaxine, nine patients stopped early because of side-effects and seven withdrew consent. At the end of treatment week 4, the median hot flash frequency dropped by 7.6 hot flashes per day for patients receiving venlafaxine and 4.85 hot flashes per day for those receiving clonidine (P = 0.025).
Conclusion: Venlafaxine is significantly more effective in reducing the frequency of hot flashes in breast cancer patients than clonidine.
Key words: breast cancer, clonidine, hot flashes, venlafaxine
Received for publication October 16, 2006. Revision received November 22, 2006. Accepted for publication November 30, 2006.
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in Ann Oncol:
- in this issue
Ann Oncol 2007 18: 613.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  C. L.H. Snozek, D. J. O'Kane, and A. Algeciras-Schimnich Pharmacogenetics of Solid Tumors: Directed Therapy in Breast, Lung, and Colorectal Cancer: A Paper from the 2008 William Beaumont Hospital Symposium on Molecular Pathology J. Mol. Diagn., September 1, 2009; 11(5): 381 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Graziottin and A. Serafini Depression and the menopause: why antidepressants are not enough? Menopause Int, June 1, 2009; 15(2): 76 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hickey, C. Saunders, A. Partridge, N. Santoro, H. Joffe, and V. Stearns Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer Ann. Onc., October 1, 2008; 19(10): 1669 - 1680. [Abstract] [Full Text] [PDF]
|
|